Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
40.18
+0.14 (0.35%)
At close: Nov 12, 2024, 4:00 PM
40.49
+0.31 (0.77%)
Pre-market: Nov 13, 2024, 4:48 AM EST
Legend Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jan '20 Jan 1, 2020 | 2019 - 2018 |
| Operating Revenue | 514.11 | 284.96 | 116.68 | 65.4 | 75 | 59.98 | Upgrade
|
| Other Revenue | 6.07 | 0.18 | 0.33 | 3.42 | - | 1.82 | Upgrade
|
| Revenue | 520.18 | 285.14 | 117.01 | 68.83 | 75 | 61.8 | Upgrade
|
| Revenue Growth (YoY) | 122.96% | 143.70% | 70.00% | -8.23% | 21.36% | 24.86% | Upgrade
|
| Cost of Revenue | 575.33 | 526.43 | 401.01 | 313.35 | 232.16 | - | Upgrade
|
| Gross Profit | -55.14 | -241.29 | -284.01 | -244.52 | -157.16 | 61.8 | Upgrade
|
| Selling, General & Admin | 263.52 | 200.93 | 174.05 | 149.5 | 72.71 | 32.37 | Upgrade
|
| Research & Development | 32.58 | - | - | - | - | 161.94 | Upgrade
|
| Operating Expenses | 296.1 | 200.93 | 174.05 | 149.5 | 72.71 | 194.31 | Upgrade
|
| Operating Income | -351.24 | -442.22 | -458.05 | -394.02 | -229.87 | -132.51 | Upgrade
|
| Interest Expense | -22.28 | -21.79 | -10.8 | -0.9 | -0.2 | -0.22 | Upgrade
|
| Interest & Investment Income | 54.49 | 54.49 | 8.18 | 0.97 | 2.93 | 4.58 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0.07 | 0.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -26.85 | -111.03 | 14.82 | -12.27 | -1.23 | -0.22 | Upgrade
|
| EBT Excluding Unusual Items | -345.89 | -520.56 | -445.85 | -406.22 | -228.29 | -127.79 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.66 | 0.66 | 0.6 | - | 0.05 | 0.47 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.23 | -0.23 | -0.48 | -0.97 | -0.06 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -79.98 | - | Upgrade
|
| Pretax Income | -345.46 | -520.12 | -445.72 | -407.2 | -308.29 | -127.32 | Upgrade
|
| Income Tax Expense | 2.67 | -1.86 | 0.63 | -3.61 | -41.91 | -25.73 | Upgrade
|
| Net Income | -348.13 | -518.25 | -446.35 | -403.58 | -266.37 | -101.59 | Upgrade
|
| Net Income to Common | -348.13 | -518.25 | -446.35 | -403.58 | -266.37 | -101.59 | Upgrade
|
| Shares Outstanding (Basic) | 182 | 176 | 159 | 141 | 118 | 100 | Upgrade
|
| Shares Outstanding (Diluted) | 182 | 176 | 159 | 141 | 118 | 100 | Upgrade
|
| Shares Change (YoY) | 6.16% | 10.71% | 12.91% | 19.21% | 18.15% | - | Upgrade
|
| EPS (Basic) | -1.91 | -2.94 | -2.81 | -2.87 | -2.25 | -1.02 | Upgrade
|
| EPS (Diluted) | -1.92 | -2.94 | -2.81 | -2.87 | -2.26 | -1.02 | Upgrade
|
| Free Cash Flow | -177.68 | -413.36 | -222.21 | -240.66 | -249.26 | -109.84 | Upgrade
|
| Free Cash Flow Per Share | -0.97 | -2.35 | -1.40 | -1.71 | -2.11 | -1.10 | Upgrade
|
| Gross Margin | -10.60% | -84.62% | -242.73% | - | -209.55% | 100.00% | Upgrade
|
| Operating Margin | -67.52% | -155.09% | -391.48% | -572.49% | -306.49% | -214.42% | Upgrade
|
| Profit Margin | -66.92% | -181.75% | -381.48% | -586.38% | -355.16% | -164.39% | Upgrade
|
| Free Cash Flow Margin | -34.16% | -144.97% | -189.91% | -349.67% | -332.35% | -177.73% | Upgrade
|
| EBITDA | -340.18 | -431.51 | -447.88 | -385.88 | -223.63 | -129.35 | Upgrade
|
| EBITDA Margin | -65.40% | -151.33% | - | - | -298.17% | -209.31% | Upgrade
|
| D&A For EBITDA | 11.07 | 10.7 | 10.17 | 8.14 | 6.23 | 3.16 | Upgrade
|
| EBIT | -351.24 | -442.22 | -458.05 | -394.02 | -229.87 | -132.51 | Upgrade
|
| EBIT Margin | -67.52% | -155.09% | - | - | - | -214.42% | Upgrade
|
| Revenue as Reported | 520.18 | 285.14 | 117.01 | 68.83 | 75 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.